German non-profit organization DEBRA Research GmbH, supporting those affected by epidermolysis bullosa (EB), and Denmark’s LEO Pharma announced a non-exclusive strategic partnership.

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

Keratosis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides top line data relating to the clinical trials on ...

Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.

DEBRA Research and LEO Pharma announce strategic partnership to enhance treatments for Epidermolysis Bullosa (EB), a rare skin disease with no approved treatment options ...